Montelukast vs Rituximab
Montelukast vs Rituximab: Overview
This comparison examines the pharmacological differences between Montelukast and Rituximab.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.
Pharmacokinetics
Half-life: Montelukast β 2.7-5.5 hours; Rituximab β 22 days.
Chemical Properties
Molecular Formula: Montelukast β C35H36ClNO3S.
Molecular Weight: Montelukast β 586.1800 g/mol.
Type: Montelukast β Small molecule; Rituximab β Antibody.